SummaryRMgm-5554
|
Successful modification | The gene/parasite could not be changed/generated by the genetic modification. |
The following genetic modifications were attempted | Gene disruption |
Number of attempts to introduce the genetic modification | Unknown |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 38624215 |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. yoelii |
Parent strain/line | P. y. yoelii 17XNL |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
Attempts to generate the mutant parasite were performed by | |
Name PI/Researcher | Feng X, Cheng Y |
Name Group/Department | Department of Public Health and Preventive Medicine, Laboratory of Pathogen Infection and Immunity, |
Name Institute | Wuxi School of Medicine, Jiangnan University |
City | Wuxi |
Country | China |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PYYM_1014900 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1431400 | ||||||||||||||||||||||||
Gene product | Surface-related antigen SRA | ||||||||||||||||||||||||
Gene product: Alternative name | SRA | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | CRISPR/Cas9 construct: integration through double strand break repair | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | Complete and partial disruption attempted | ||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | The unsuccessful attempts to disrupt this gene indicate an essential function during asexual blood stage growth/multiplication P. falciparum surface-related antigen (SRA) is located on the surface of merozoites and gametocytes, exported to the surface of infected erythrocyte membranes, and reported to bind to human erythrocytes. The PySRA protein contains a signal peptide (aa 1–24) and a transmembrane domain (aa 853–871) Different protein segements: PySRA-F1 (aa 24–298), PySRA-F2 (aa 299–548), and PySRA-F3 (aa 705–852) Complete PySRA and PySRA-f2 could not be knocked out/disrupted From the Abstract: This study found that the F2 segment of P. yoelii SRA activated downstream MAPK and NF-κB signaling pathways by binding to CD68 on the surface of the macrophage membrane and regulating the inflammatory response. The anti-PySRA-F2 antibody can protect mice against P. yoelii, and the pro-inflammatory responses such as IL-1β, TNF-α, and IL-6 after infection with P. yoelii are attenuated. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
![]()
| |||||||||||||||||||||||||
top of page |